{"id":809706,"date":"2025-02-06T07:05:08","date_gmt":"2025-02-06T12:05:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/"},"modified":"2025-02-06T07:05:08","modified_gmt":"2025-02-06T12:05:08","slug":"opthea-wet-amd-data-featured-at-macula-society-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/","title":{"rendered":"Opthea Wet AMD Data Featured at Macula Society Meeting"},"content":{"rendered":"
\n

MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th<\/sup> Annual Meeting being held\u00a0\u00a0 February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases.<\/p>\n

Details are as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Session:<\/td>\nNeovascular AMD I: Trials<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Timing:<\/td>\nFriday, February 14, 2025, 8:00 to 8:05 AM ET<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Presentation:<\/td>\nSozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Presenter:<\/td>\nDavid S. Boyer, MD<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Program:<\/td>\n\n https:\/\/www.xcdsystem.com\/maculasociety\/program\/5G2onFx\/index.cfm?pgid=397&RunRemoveSessionFilter=1<\/a>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial demonstrating that superior vision and anatomic outcomes were observed with sozinibercept 2 mg combination therapy, compared with standard-of-care ranibizumab alone, with baseline angiographic lesion characteristics predictive of response.<\/p>\n

\n About Opthea<\/strong>\n <\/p>\n

Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age\u2010related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.<\/p>\n

Opthea\u2019s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C\/D \u2018trap\u2019 inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.<\/p>\n

To learn more, visit our website at www.opthea.com<\/a> and follow us on X<\/a> and LinkedIn<\/a>.<\/p>\n

Authorized for release to ASX by Frederic Guerard, PharmD, CEO<\/p>\n\n\n\n
\n Investor Inquiries<\/strong><\/p>\n

PJ Kelleher\u00a0
LifeSci Advisors, LLC\u00a0
Email: pkelleher@lifesciadvisors.com<\/a>
Phone: 617-430-7579\u00a0<\/td>\n

\n Media\u00a0Inquiries<\/strong>\u00a0<\/p>\n

Silvana Guerci-Lena\u00a0
NorthStream Global Partners\u00a0
Email: silvana@nsgpllc.com<\/a>\u00a0<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Join our email database to receive program updates:\u00a0\u00a0
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com<\/u><\/a> Web: www.opthea.com<\/u><\/a>\u00a0\u00a0\u00a0<\/p>\n

Source: Opthea Limited<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held\u00a0\u00a0 February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. Details are as follows: Session: Neovascular AMD I: Trials \u00a0 \u00a0 Timing: Friday, February 14, 2025, 8:00 to 8:05 AM ET \u00a0 \u00a0 Presentation: Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study … <\/p>\n

Continue reading “Opthea Wet AMD Data Featured at Macula Society Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809706","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOpthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held\u00a0\u00a0 February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. Details are as follows: Session: Neovascular AMD I: Trials \u00a0 \u00a0 Timing: Friday, February 14, 2025, 8:00 to 8:05 AM ET \u00a0 \u00a0 Presentation: Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study … Continue reading "Opthea Wet AMD Data Featured at Macula Society Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T12:05:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opthea Wet AMD Data Featured at Macula Society Meeting\",\"datePublished\":\"2025-02-06T12:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/\",\"name\":\"Opthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==\",\"datePublished\":\"2025-02-06T12:05:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-wet-amd-data-featured-at-macula-society-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opthea Wet AMD Data Featured at Macula Society Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Opthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk","og_description":"MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held\u00a0\u00a0 February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. Details are as follows: Session: Neovascular AMD I: Trials \u00a0 \u00a0 Timing: Friday, February 14, 2025, 8:00 to 8:05 AM ET \u00a0 \u00a0 Presentation: Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study … Continue reading \"Opthea Wet AMD Data Featured at Macula Society Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T12:05:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opthea Wet AMD Data Featured at Macula Society Meeting","datePublished":"2025-02-06T12:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/","name":"Opthea Wet AMD Data Featured at Macula Society Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==","datePublished":"2025-02-06T12:05:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzk2MyM2NzM4NDU5IzUwMDEyMTgwNg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-wet-amd-data-featured-at-macula-society-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opthea Wet AMD Data Featured at Macula Society Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809706"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809706\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}